Mantle Cell Lymphoma - 26 Studies Found
| Completed |
: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients : Mantle Cell Lymphoma : 2025-08-03 : Given by PO |
| COMPLETED |
: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2025-08-03 : The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for do |
| COMPLETED |
: Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2025-08-03 : Acalabrutinib 100 mg BID will be self-administered orally starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, |
| COMPLETED |
: Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial : Recurrent Mantle Cell Lymphoma : 2025-08-03 : Undergo blood, saliva or tissue sample collection |
| COMPLETED |
: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2025-08-03 : Bendamustine will be administered at a dose of 90 mg/m^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3 |
| COMPLETED |
: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) : Relapsed/Refractory Mantle Cell Lymphoma : 2025-08-03 : Administered intravenously |